Table 1

Study population characteristics by estrogenic botanical supplement (EBS) use

No. non-EBS users (%)

No. EBS users (%)

P valuea

N = 464

N = 303


Study site

0.12

Western Washington

90 (19.4)

70 (23.1)

New Mexico

259 (55.8)

146 (48.2)

Los Angeles County

115 (24.8)

87 (28.7)

Race

0.63

Non-Hispanic white

281 (60.6)

173 (57.1)

African-American

115 (24.8)

88 (29.0)

Hispanic

53 (11.4)

33 (10.9)

Others

15 (3.2)

9 (3.0)

Education

< 0.0001

≤ High school

143 (30.8)

51 (16.8)

Technical school or some college

154 (33.2)

126 (41.6)

College graduate

167 (36.0)

126 (41.6)

Mean age at diagnosis (SDb), years

56.0 (10.6)

52.5 (8.7)

< 0.0001c

Stage at diagnosis

0.41

In situ

110 (23.7)

60 (19.8)

Localized

257 (55.4)

173 (57.1)

Regional

97 (20.9)

70 (23.1)

Breast cancer treatment

0.43

No radiation and no chemotherapy

155 (33.4)

86 (28.4)

Radiation only

171 (36.9)

116 (38.3)

Chemotherapy only

45 (9.7)

29 (9.6)

Radiation and chemotherapy

93 (20.0)

72 (23.8)

Tamoxifen use

0.24

No

248 (53.5)

175 (57.8)

Yes

216 (46.6)

128 (42.2)

Medical comorbidity

0.007

None

332 (71.6)

243 (80.2)

1 or more condition(s)

132 (28.5)

60 (19.8)

Activity level within the past year of 30-month interview from sports/recreation (MET hours/week)

< 0.0001

0

93 (20.0)

33 (10.9)

0.1-8.9

201 (43.3)

115 (38.0)

≥ 9

170 (36.6)

155 (51.2)

Menopausal status at 30-month interview

0.01

Premenopausal

74 (16.0)

68 (22.4)

Postmenopausal

Never HTd after diagnosis

193 (41.6)

135 (44.6)

Ever HTd after diagnosis

172 (37.1)

80 (26.4)

Unknown

25 (5.4)

20 (6.6)

Body mass index at 30-month interview (kg/m2)

0.13

< 25

180 (38.8)

128 (42.2)

25-29

133 (28.7)

97 (32.0)

≥ 30

151 (32.5)

78 (25.7)

Mean isoflavones from soy-containing foods (SDb), mg/day

1.9 (9.4)

4.0 (9.9)

0.002c


aP-value ascertained from Pearson χ2 test, except where otherwise noted. bSD, standard deviation. cP-value from t test. dHT, hormone therapy.

Ma et al. BMC Complementary and Alternative Medicine 2011 11:109   doi:10.1186/1472-6882-11-109

Open Data